The financial burden of rotavirus disease in four countries of the European union

Pediatric Infectious Disease Journal

Volumn 27, Issue 1 SUPPL., 2008, Pages

  Standaert, Baudouin ^a,d   Harlin, Olof ^b   Desselberger, Ulrich ^c  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b Archimed Medical Communication AG   (Switzerland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d GSK   (Belgium)

Author keywords

Disease burden; Economic cost; Europe; Rotavirus

Indexed keywords

ARTICLE; BELGIUM; EUROPEAN UNION; FAMILY LEAVE; FINANCIAL MANAGEMENT; FRANCE; HEALTH CARE COST; HUMAN; NETHERLANDS; PRIORITY JOURNAL; ROTAVIRUS; UNITED KINGDOM; VACCINATION; VIRAL GASTROENTERITIS;

EID: 37549007628     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e31815eee1a     Document Type: Article

References (46)

1. Parashar UD, Bresee JS, Gentsch JR, Glass RI. Rotavirus. Emerg Infect Dis. 1998;4:561-570.
2. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565-572.
3. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12:304-306.
4. Koopmans M, Brown D. Seasonality and diversity of Group A rotaviruses in Europe. Acta Paediatr Suppl. 1999;88:14-19.
5. Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen M. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis. 2007;195(suppl 1):S36-S44.
6. Van Damme P, Van der Wielen M, Ansaldi F, et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis. 2006;6:805-812.
7. Djuretic T, Ramsay M, Gay N, Wall P, Ryan M, Fleming D. An estimate of the proportion of diarrhoeal disease episodes seen by general practitioners attributable to rotavirus in children under 5 y of age in England and Wales. Acta Paediatr Suppl. 1999;88:38-41.
8. Ryan MJ, Ramsay M, Brown D, Gay NJ, Farrington CP, Wall PG. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis. 1996;174(suppl 1):S12-S18.
9. Melliez H, Boelle PY, Baron S, Mouton Y, Yazdanpanah Y. Morbidity and cost of rotavirus infections in France. Med Mal Infect. 2005;35:492-499.
10. Brandt CD, Kim HW, Rodriguez WJ, et al. Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol. 1983;18:71-78.
11. Fourquet F, Desenclos JC, Maurage C, Baron S. Acute gastro-enteritis in children in France: estimates of disease burden through national hospital discharge data. Arch Pediatr. 2003;10:861-868.
12. Law A, Kelton W. Simulation Modeling and Analysis. 3rd ed. Boston, MA: McGraw Hill Higher Education; 2000.
13. Giaquinto C, Van Damme P, Huet F, et al. Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis. 2007;195(suppl 1):S26-S35.
14. Clemens J, Rao M, Ahmed F, et al. Breast-feeding and the risk of life-threatening rotavirus diarrhea: prevention or postponement? Pediatrics. 1993;92:680-685.
15. Newburg DS, Peterson JA, Ruiz-Palacios GM, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. Lancet. 1998;351:1160-1164.
16. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22:259-267.
17. Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J. 2006;25(1 suppl):S12-S21.
18. OECD in Figures 2006-2007. 2006. Available at: www.oecd.org/infigures. Accessed July 6, 2007.
19. Kemmeren JM, Mangen M-JJ, van Duynhoven YTHP, Havelaar AH. Rotavirus, in Priority Setting of Food Borne Pathogens. Disease Burden and Costs of Selected Enteric Pathogens. RIVM report 330080001/2006. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment); 2006.
20. Official medical tariff list (UCANSS). Ucanss 2006. June 22, 2007. Available at: http://www.ucanss.fr/. Accessed July 1, 2007.
21. Fruytier AC, Van Schoor J, Standaert B. Vaccination with RIX4414 is cost-effective in a Belgian setting (Poster PIH3). Presented at: ISPOR 9th Annual Congress; October 29, 2006; Copenhagen, DK.
22. Harris JP, Jit M, Cooper D, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. I. Estimating the burden of disease. Vaccine. 2007;25:3962-3970.
23. Martinot A, Dumonceaux A, Grandbastien B, Hue V, Leclerc F. Reseau interhospitalier d'evaluation des pratigues medicales dans les affections courantes de l'enfant. Evaluation of the ambulatory treatment of acute diarrhea in infants. Arch Pediatr. 1997;4:832-838.
24. de Wit MA, Koopmans MP, van der Blij JF, van Duynhoven YT. Hospital admissions for rotavirus infection in the Netherlands. Clin Infect Dis. 2000;31:698-704.
25. National Costs Study 2005. Public hospitals. 2005. Available at: www.atih.sante.fr. Accessed October 16, 2007.
26. Contactisolatie kinderen (Contact isolation children). Dutch Workingparty on Infection Prevention. 2004. Available at: http://www.wip.nl/. Accessed July 6, 2007.
27. Oostenbrink J, Koopmanschap M, Rutten F. Handleiding voor kostenonderzoek - methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg Guide to Cost Research - Methods and Standard Costs Prices for Economic Evaluations in Healthcare. Amstelveen: College voor zorgverzekeringen (Health Care Insurance board); 2004.
28. Oostenbrink R, Moons KG, Derksen-Lubsen AG, Grobbee DE, Moll HA. A diagnostic decision rule for management of children with meningeal signs. Eur J Epidemiol. 2004;19:109-116.
29. Sermet-Gaudelus I, de La RF, Salomon JL, et al. Rotavirus nosocomial infection in pediatric units. A multicentric observation study. Pathol Biol (Paris). 2004;52:4-10.
30. Harrington M, Butler K, Cafferkey M. Rotavirus infection in hospitalised children: incidence and impact on healthcare resources. Ir J Med Sci. 2003;172:33-36.
31. Le T, Gibson J, Oxley L. Cost- and income-based measures of human capital. J Econ Surv. 2007;17:271-307.
32. Directionate General of Human Rights. Parental Leave in Council of Europe Member States. Strasbourg: Council of Europe; 2005:1-50.
33. European Foundation for the Improvement of Living and Working Conditions. Parental leave in European companies: establishment survey on working time 2004-2005. Dublin, Ireland: European Foundation for the Improvement of Living and Working Conditions; 2007:1-57.
34. Moss P, O'Brien M. International review of leave policies and related research 2006. UK: Department of Trade and Industry; 2006. Employment relations research series no. 57.
35. Guide sécurité sociale de l'employeur. L'Union des Caisses Nationales de Sécurité Sociale. 2006. Available at: http://www.ucanss.fr/services/textes_documents/gsse/accueil_gsse.htm.
36. Interruption de carrière dans le cadre du congé parental. NEO - National employment office. 2007. Available at: http://www.onem.fgov.be/ D_opdracht_LBO/Regl/Werknemers/ouderschap/Ov_Cp/ContentFR.htm#TopOfPage.
37. Time off for dependants: a guide for employers and employees (UK). Department of Trade and Industry (UK). 2000. Available at: http://www.berr.gov. uk/files/file11419.pdf.
38. Bevolking, geboorte. (Population, birth). Centraal Bureau voor de Statistiek, Voorburg/Heerlen. 2007. Available at: www.statline.cbs.nl. Accessed July 9, 2007.
39. Mid-2005 population estimates. Office of National Statistics. 2007. Available at: http://www.statistics.gov.uk/statbase/Expodata/Spreadsheets/D9387. xls.
40. Al MJ, Goossens L, Hövels AM, Michielsen CP, Standaert B. Costeffectiveness of mass vaccination with a rotavirus vaccine in the Netherlands (Poster PIN19). Presented at: ISPOR 9th Annual Congress; October 30, 2006; Copenhagen, DK.
41. Martin A, Standaert B. Cost effectiveness of infant vaccination with Rotarix in the UK. Presented at: 25th Annual Meeting of the European Society for Paediatric Infectious Diseases, ESPID; 2007; Porto, Portugal.
42. Bilcke J, Beutels P, De Smet F, Hanquet G, Van Ranst M, Van Damme P. Vaccination des nourrissons contre le rotavirus en Belgique. Analyse coût-efficacité. KCE reports 54B. Bruxelles, Belgium: Centre fédéral d'expertise des soins de santé (KCE); 2007.
43. Huet F, Largeron N, Trichard M, Miadi-Fargier H, Jasso-Mosqueda G. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. Vaccine. 2007;25:6348-6358.
44. Lorgelly PK, Joshi D, Iturriza GM, Gray J, Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect. 2007:1-12.
45. Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics. 2005;23:105-111.
46. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics. 2007;119:684-697.